纳武利尤单抗联合伊匹木单抗或纳武利尤单抗单药治疗黑色素瘤脑转移:多中心随机2期研究
这项多中心开放标签随机2期研究纳入免疫治疗初治的黑色素瘤脑转移患者,评估纳武利尤单抗联合伊匹木单抗(A队列)或纳武利尤单抗单药(B队列)的颅内疗效。结果显示A队列颅内缓解率46%(95%CI 29-63),B队列20%(7-41),C队列6%(0-30)。联合方案颅内活性高,应考虑作为无症状未治疗脑转移患者的一线治疗。
要点
- 纳武利尤单抗联合伊匹木单抗颅内缓解率46%,单药为20%。
- 联合组3/4级治疗相关不良事件发生率54%,单药组16%。
- 联合方案可考虑作为无症状未治疗黑色素瘤脑转移一线治疗。
核心结论
- 纳武利尤单抗联合伊匹木单抗和纳武利尤单抗单药在黑色素瘤脑转移中均具有活性。
- 联合方案使高比例患者获得颅内缓解,应考虑作为无症状未治疗脑转移患者的一线治疗。
研究设计与样本
- 多中心开放标签随机2期试验,在澳大利亚4个中心开展。
- 纳入免疫治疗初治的18岁及以上黑色素瘤脑转移患者,分为3个队列。
- 无症状且未接受过局部脑治疗的患者按30:24比例随机分配至A队列(纳武利尤单抗联合伊匹木单抗)或B队列(纳武利尤单抗)。
- 局部治疗失败、有神经系统症状或软脑膜病变的患者入组非随机C队列(纳武利尤单抗)。
- 共入组79例患者:A队列36例,B队列27例,C队列16例。
主要发现
- 中位随访17个月(IQR 8-25)时,A队列35例中16例(46%;95%CI 29-63)达到颅内缓解。
- B队列25例中5例(20%;95%CI 7-41)达到颅内缓解。
- C队列16例中1例(6%;95%CI 0-30)达到颅内缓解。
- A队列6例(17%)、B队列3例(12%)达到颅内完全缓解,C队列无完全缓解。
- 治疗相关不良事件发生率:A队列34/35例(97%),B队列17/25例(68%),C队列8/16例(50%)。
关键数值与推荐
- A队列方案:静脉纳武利尤单抗1 mg/kg联合伊匹木单抗3 mg/kg每3周共4次,随后纳武利尤单抗3 mg/kg每2周。
- B队列和C队列方案:静脉纳武利尤单抗3 mg/kg每2周。
- 主要终点为第12周起的颅内缓解。
临床怎么用
- 对于无症状且未接受过局部治疗的黑色素瘤脑转移患者,可考虑纳武利尤单抗联合伊匹木单抗作为一线治疗。
- 联合方案颅内缓解率较高,但3/4级治疗相关不良事件发生率也较高,需权衡毒性。
局限性
- 研究为2期试验,样本量较小。
- C队列为非随机队列,样本量仅16例。
- 最终生存分析仍在进行中。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Nivolumab monotherapy and combination nivolumab plus ipilimumab increase proportions of patients achieving a response and survival versus ipilimumab in patients with metastatic melanoma; however, efficacy in active brain metastases is unknown. We aimed to establish the efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with active melanoma brain metastases. METHODS: This multicentre open-label randomised phase 2 trial was done at four sites in Australia, in three cohorts of immunotherapy-naive patients aged 18 years or older with melanoma brain metastases. Patients with asymptomatic brain metastases with no previous local brain therapy were randomly assigned using the biased coin minimisation method, stratified by site, in a 30:24 ratio (after a safety run-in of six patients) to cohort A (nivolumab plus ipilimumab) or cohort B (nivolumab). Patients with brain metastases in whom local therapy had failed, or who had neurological symptoms, or leptomeningeal disease were enrolled in non-randomised cohort C (nivolumab). Patients in cohort A received intravenous nivolumab 1 mg/kg combined with ipilimumab 3 mg/kg every 3 weeks for four doses, then nivolumab 3 mg/kg every 2 weeks; patients in cohort B or cohort C received intravenous nivolumab 3 mg/kg every 2 weeks. The primary endpoint was intracranial response from week 12. Primary and safety analyses were done on an intention-to-treat basis in all patients who received at least one dose of the study drug. This trial is registered with ClinicalTrials.gov, number NCT02374242, and is ongoing for the final survival analysis. FINDINGS: Between Nov 4, 2014, and April 21, 2017, 79 patients were enrolled; 36 in cohort A, 27 in cohort B, and 16 in cohort C. One patient in cohort A and two in cohort B were found to be ineligible and excluded from the study before receiving the study drug. At the data cutoff (Aug 28, 2017), with a median follow up of 17 months (IQR 8-25), intracranial responses were achieved by 16 (46%; 95% CI 29-63) of 35 patients in cohort A, five (20%; 7-41) of 25 in cohort B, and one (6%; 0-30) of 16 in cohort C. Intracranial complete responses occurred in six (17%) patients in cohort A, three (12%) in cohort B, and none in cohort C. Treatment-related adverse events occurred in 34 (97%) of 35 patients in cohort A, 17 (68%) of 25 in cohort B, and eight (50%) of 16 in cohort C. Grade 3 or 4 treatment-related adverse events occurred in 19 (54%) patients in cohort A, four (16%) in cohort B, and two (13%) in cohort C. No treatment-related deaths occurred. INTERPRETATION: Nivolumab combined with ipilimumab and nivolumab monotherapy are active in melanoma brain metastases. A high proportion of patients achieved an intracranial response with the combination. Thus, nivolumab combined with ipilimumab should be considered as a first-line therapy for patients with asymptomatic untreated brain metastases. FUNDING: Melanoma Institute Australia and Bristol-Myers Squibb.
引用
- Long GV, Atkinson V, Lo S, et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol. 2018. PMID: 29602646. doi:10.1016/S1470-2045(18)30139-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。